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Abstract
Despite being the most common electrolyte disturbance encountered in clinical practice, the diag-
nosis and treatment of hyponatremia (defined as a serum sodium concentration <135 mmol/L)
remains far from optimal. This is extremely troubling because not only is hyponatremia associated
with increased morbidity, length of hospital stay and hospital resource use, but it has also been
shown to be associated with increased mortality. The reasons for this poor management may
partly lie in the heterogeneous nature of the disorder; hyponatremia presents with a variety of
possible etiologies, differing symptomology and fluid volume status, thereby making its diagnosis
potentially complex. In addition, a general lack of awareness of the clinical impact of the disorder,
a fear of adverse outcomes through overcorrection of sodium levels, and a lack of effective tar-
geted treatments until recent years, may all have contributed to a reticence to actively treat cases
of hyponatremia. There is therefore a clear unmet need to further educate physicians on the patho-
physiology, diagnosis and management of this important condition. Through the use of a variety of
real-world cases of patients with hyponatremia secondary to the syndrome of inappropriate
secretion of antidiuretic hormone—a condition that accounts for approximately one-third of all
cases of hyponatremia—this supplement aims to provide a comprehensive overview of the chal-
lenges faced in diagnosing and managing hyponatremia. These cases will also help to illustrate
how some of the limitations of traditional therapies may be overcome with the use of vasopressin
receptor antagonists.
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Introduction
M. Laville
Hyponatremia, defined as a serum sodium concentration
([Na+]) <135 mmol/L, is the most common electrolyte dis-
turbance encountered in clinical practice, affecting up to
15–28% of hospitalized patients [1, 2]. Its incidence varies
between hospitals and departments; for example, a study
in the Netherlands observed an increased incidence in the
departments of surgery (32%), internal medicine (36%)
and intensive care (38%) compared with other depart-
ments (P < 0.05) [3]. Patients with hyponatremia also have
varied clinical presentations including differing sympto-
mology, underlying etiology and fluid volume status.
Despite frequently being observed in both outpatients
and hospitalized patients, the diagnosis and management
of hyponatremia remains far from optimal [4, 5]. This may
be attributable to the diversity of underlying disease
states associated with the condition and, until the last few
years, a lack of targeted treatments. In some cases, the
failure to order sufficient tests for diagnosis may also
compound this issue [4].
Rationale for the treatment of hyponatremia
Hyponatremia at admission has been shown to be associ-
ated with increased length of stay (LOS) and cost of care
for hospitalized patients [6]. Consequently, the proactive
treatment of hyponatremia has the potential to reduce
the utilization of healthcare resources.
There is some debate regarding the relationship of hypo-
natremia with mortality. A prospective study in 98 411
patients followed up for up to 5 years after hospital dis-
charge found that even mild hyponatremia (serum [Na+]
<135 mmol/L) independently predicted mortality [7]. More-
over, the resolution of the hyponatremia during hospitaliz-
ation attenuated the increased mortality risk. The presence
© The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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of hyponatremia has also been found to be an independent
risk factor for increased mortality in a wide range of under-
lying diseases, including congestive heart failure, tuberculo-
sis and liver failure [2]. Despite these data, causality has
been difficult to prove [8, 9]. For example, in an analysis of
hospitalized patients with hyponatremia, Chawla et al. [9]
hypothesized that the nature of the underlying disease
rather than hyponatremia itself was responsible for mor-
tality. However, another plausible explanation is that hypo-
natremia may contribute to organ dysfunction and,
therefore, indirectly contribute tomortality (Figure 1) [8].
Support for this latter hypothesis is increasing with
emerging data revealing the presence of significant mor-
bidity in patients with hyponatremia, even in those tra-
ditionally presumed to be asymptomatic. In the past,
treatment for the condition was only considered in
patients with severe hyponatremia (serum [Na+] <125
mmol/L); however, even mild hyponatremia has been
shown to be associated with attention deficits, increased
falls and unsteadiness, which improved with the correc-
tion of hyponatremia [10]. Moreover, hyponatremia has
also been shown to place elderly patients at increased risk
of osteoporosis and bone fractures [11, 12]. Such symp-
toms are suggestive of a potential effect of hyponatremia
on the nervous system and bone [8].
The syndrome of inappropriate secretion
of antidiuretic hormone
Approximately one-third of all cases of hyponatremia are ac-
counted for by the syndrome of inappropriate secretion of
antidiuretic hormone (SIADH) [13], a condition first described
by Bartter and Schwartz [14]. Hyponatremia secondary to
SIADH is the focus of our patient case reviews in this sup-
plement. In a healthy body, vasopressin [also known as argi-
nine vasopressin (AVP) or antidiuretic hormone (ADH)] acts in
response to an increase in serum osmolality to retain water
at the kidney nephron. As its name implies, patients with
SIADH have unregulated secretion of vasopressin despite hy-
potonicity of the serum. Consequently, water intake com-
bined with a high concentration of vasopressin leads to
antidiuresis eventually resulting in hyponatremia.
Research over the past 40 years has uncovered a long
list of potential causes of SIADH; these causes can be ca-
tegorized as related to malignant diseases, pulmonary
diseases and disorders of the central nervous system, as
well as idiopathic forms [15]. Criteria now exist to defini-
tively diagnose the condition, with the clinical assessment
of the patient’s fluid status forming a key part (Table 1).
The management of SIADH
Owing to a relative lack of randomized controlled trials,
the treatment of SIADH is largely based on expert opinion
and uses agents commonly approved for indications other
than for hyponatremia [16]. Fortunately, this situation has
recently improved with the advent of vasopressin receptor
antagonists (also known as ‘vaptans’; see below).
Proper evaluation of the underlying cause of SIADH is
essential for its appropriate management. Once a diagno-
sis has been made, several conventional strategies exist
for the correction of sodium concentration, many of which
involve agents approved for indications other than for hy-
ponatremia. These treatment strategies include fluid re-
striction, demeclocycline, lithium, loop diuretics in
combination with salt tablets, urea tablets and hypertonic
saline (3% NaCl). Owing to the absence of randomized
controlled trials, the treatment of SIADH is largely based
on expert opinion using agents commonly approved for
indications other than for hyponatremia. However, these
strategies can often prove challenging (Table 2), and there
is little consensus as to the most effective and safe strat-
egy in any given patient [16]. Although fluid restriction
has traditionally been the mainstay of treatment in the
management of SIADH despite the absence of an evi-
dence base for its use, correct implementation is often dif-
ficult and patients can find it unpleasant, thus leading to
poor compliance [17]. In fact, fluid restriction is often pre-
scribed because of a lack of access to alternatives or simply
because it is considered to be cheap. This is despite the fact
that the majority of nephrologists and endocrinologists in
Europe are dissatisfied with its effectiveness as a therapy for
SIADH, as well as its poor tolerance by patients and feasi-
bility even in trained staff [18].
Figure 1: Possible relationships between hyponatremia and mortality [8]. The figure illustrates possible scenarios to explain the relationship between
hyponatremia and mortality. In one scenario, hyponatremia and mortality are both caused by severe underlying disease. In another scenario,
hyponatremia directly results in mortality (e.g. hyponatremia leading to cerebral edema in acute hyponatremia and the osmotic demyelination syndrome
when chronic hyponatremia is corrected too rapidly). In the final scenario, hyponatremia indirectly contributes to mortality by causing organ dysfunction.
Adapted from Hoorn and Zietse [8].
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The advent of vasopressin receptor antagonists
The recent introduction of orally available (tolvaptan)
and parenteral (conivaptan) antagonists to the renal
vasopressin receptor represents a new era in the manage-
ment of SIADH. For the first time, agents are available that
are specifically approved for the treatment of SIADH.
Vaptans work by preventing the antidiuresis caused by
circulating vasopressin, by competitively blocking the
binding of vasopressin to V2 receptors in the distal nephron
of the kidney [19]. This decreases cAMP production, in turn
reducing the number of aquaporin-2 water channels in the
cells of the collecting tubules, which leads to a decrease in
water reabsorption. The end result is electrolyte-free water
excretion, or aquaresis, without any significant effects on
renal sodium and potassium excretion. Thus, the removal
of water from the body without loss of electrolytes results
in an increase in serum [Na+].
Tolvaptan
In the European Union, tolvaptan—the only orally adminis-
tered vaptan—is approved for use in adults with hypona-
tremia secondary to SIADH [20]. However, in the USA it is
indicated for patients with clinically significant euvolemic
or hypervolemic hyponatremia (serum [Na+] <125 mmol/L)
and also for mild hyponatremia (serum [Na+] <125–135
mmol/L) in symptomatic patients, including patients with
heart failure and SIADH that has resisted conventional
therapy [21].
Its efficacy was evaluated in two of the largest studies
ever conducted in hyponatremia [22]. These two identical
multicenter, randomized, double-blind, placebo-controlled
studies—known as the Study of Ascending Levels of Tol-
vaptan in Hyponatremia (SALT-1 and -2)—enroled 448
patients with euvolemic or hypervolemic hyponatremia
(serum [Na+] <135 mmol/L) of different etiologies. Patients
were randomized to receive tolvaptan (15–60 mg/day) or
placebo for 30 days.
Tolvaptan significantly raised serum [Na+] within 8 h after
its first administration in both the total patient population
and subgroups categorized by degree of hyponatremia at
baseline (all P < 0.01) [22]. Moreover, significantly more
patients in the tolvaptan-treated group had normal serum
[Na+] values at 30 days compared with placebo (P < 0.001).
The most common adverse events were thirst and dry
mouth; other adverse events included dizziness, hypoten-
sion, acute renal failure, sepsis and ascites. Furthermore, no
patients exhibited any neurological symptoms suggestive of
osmotic demyelination.
A subgroup analysis confirmed that the efficacy and
safety profile of tolvaptan demonstrated in the hetero-
geneous hyponatremic population enroled in the SALT trials
Table 1. Essential and supporting diagnostic criteria for hyponatremia
secondary to SIADH [15]
Essential diagnostic criteria
Case 3
values
Case 4
values
Serum sodium <135 mmol/L 121 141
Decreased measured plasma osmolality
(<275 mOsm/kg)
259 267
Urinary osmolality >100 mOsm/kg during
hypotonicity
307 646
Clinical euvolemia ✓ ✓
- No clinical signs of contraction of
extracellular fluid (e.g. no orthostasis,a
tachycardia, decreased skin turgor or dry
mucous membranes)
- No clinical signs of expansion extracellular
fluid (e.g. no edema or ascites)
Increased urinary sodium excretion >30 mmol/L
with normal dietary salt and water intakeb
89 130
Normal thyroid and adrenal function
determined by both clinical and laboratory
assessment
✓ ✓d
No recent use of diuretic agents ✓ ✓
Supporting diagnostic criteria
Plasma uric acid <4 mg/dL (<0.24 mmol/L) ✓
Blood urea nitrogen <10 mg/dL (<3.6 mmol/L)
Fractional sodium excretion >1%; fractional
urea excretion >55%c
Failure to improve hyponatremia after 0.9%
saline infusion
Improvement of hyponatremia with fluid
restriction
aOrthostatic changes in blood pressure and pulse rate are defined as a
≥20 mm decrease in systolic blood pressure and/or a ≥20 b.p.m. increase
upon going from a supine to a standing position.
bAlthough high urine sodium excretion generally occurs in patients with
SIADH, its presence does not confirm the diagnosis, nor does its absence
rule out the diagnosis; urine [Na+] can also be high in patients with
Addison’s disease. Conversely, some patients with SIADH can have low
urinary [Na+] if they become hypovolemic or solute depleted, which are
conditions sometimes produced by imposed sodium and water restriction.
cFractional sodium excretion = (urinary sodium excretion/serum sodium)/
(urinary creatinine/serum creatinine) × 100; fractional urea
excretion = (urinary urea/serum urea)/(urinary creatinine/serum
creatinine) × 100.
dThe patient was taking corticosteroids.
Adapted from Ellison and Berl [15].
Table 2. Challenges of conventional treatments for SIADH [16]
Strategy Licensed in EU for SIADH
Drawback
Slow and of low efficiency Unreliable Cumbersome Invasive
Fluid restriction ⨯ ✓ ✓
3% NaCl ⨯ ✓
Loop diuretic ⨯ ✓
Urea ⨯ ✓
Demeclocycline ⨯ ✓ ✓
Lithium ⨯ ✓ ✓
CVVH ⨯ ✓ ✓
SLEDD ⨯ ✓ ✓
CVVH, continuous veno-venous hemofiltration; SLEDD, slow low-efficiency daily dialysis.
Adapted from Gross [16].
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was applicable to patients with a diagnosis of SIADH [17].
According to the randomized design of the study, 58
patients with SIADH were assigned to receive placebo and
52 were assigned to receive tolvaptan at 15–60 mg/day.
This was the largest number of patients with SIADH studied
chronically using an orally active, vasopressin V2 receptor
antagonist to correct hyponatremia. The authors noted
that, ‘the superiority of tolvaptan over placebo was appar-
ent for all of the endpoints related to improvement in
serum [Na+] in the SIADH subgroup (average daily AUC of
change from baseline in serum [Na+] at Days 4 and 30,
mean serum [Na+] at each visit, time to serum [Na+] nor-
malization, percentage of subjects with serum [Na+] nor-
malization at Days 4 and 30, and categorical change in
serum [Na+] at Days 4 and 30)’. Regarding safety issues, the
profiles of potentially drug-related adverse events were
relatively similar between the two treatment groups. Thirst
and dry mouth occurred in nine (18%) and eight (16%)
patients, respectively, on tolvaptan, and five (9%) and six
(10%) patients, respectively, on placebo in this SIADH sub-
group analysis. Of the 51 patients treated with tolvaptan,
three (5.9%) exceeded an increase in serum [Na+] >12
mmol/L over the first 24 h and >18 mmol/L over the first 48
h; however, none of these patients experienced any neuro-
logical symptoms suggestive of osmotic demyelination.
The long-term efficacy and safety of tolvaptan was con-
firmed in an open-label extension trial, SALTWATER, which
enroled 111 patients who completed the SALT-1 and
SALT-2 studies for a mean of 701 days [23].
Upcoming guidelines for the management
of hyponatremia
With the development of the vaptans, it has been
suggested that these agents may become the mainstay of
treatment for SIADH. However, there is a clear need for
further randomized, controlled trials assessing the relative
benefits of these new pharmacological agents compared
with traditional standards of care. While we await the
completion of these trials, the role of these newer agents in
current practice has been considered in recently published
evidence-based and expert panel reviewed guidelines
in the USA (Verbalis JG, Goldsmith SR, Greenberg A et al.
Diagnosis, evaluation, and treatment of hyponatremia:
expert panel recommendations. Am J Med 2013; 126
(10 Suppl 1): S1–S4). European guidelines are expected to
follow later this year.
A review of real-life cases
For a condition that is frequently encountered in clinical
practice and has the clinical consequences that hyponatre-
mia does, its suboptimal diagnosis andmanagement are a
serious cause for concern. Furthermore, even when the
condition is diagnosed, traditional treatment options may
exhibit limited efficacy and can be challenging to use.
There is, therefore, an urgent need for improved edu-
cation regarding the diagnosis and management of this
important condition. To address these issues, a series of
case studies have been brought together in this sup-
plement to facilitate the exchange of knowledge regarding
the management of hyponatremia. Discussion of these
case studies will provide detailed information on the diag-
nosis and management of patients with hyponatremia
secondary to SIADH. In addition, these cases illustrate the
potential advantages that vaptans may offer over tra-
ditional therapies in certain patients.
Case 1: 47-year-old woman with a
medulloblastoma
V. Burst
A 47-year-old woman with a known medulloblastoma (di-
agnosed 2 years previously) went to see her oncologist for
a scheduled check-up. Her existing medications included
temsirolimus for her tumor; she was also receiving treat-
ment with the anticonvulsant valproate because she had
experienced a number of seizures over the past year. At
her check-up, she reported that she had not been feeling
well for the previous few days with symptoms including
drowsiness, lethargy and headaches.
A clinical assessment revealed a fever (38.5°C) but other-
wise no other apparent issues; she had no signs of edema,
her jugular venous pressure was normal and her heart and
lungs were normal during auscultation (Table 3). Her blood
analysis reported that her serum [Na+] was low at 123
mmol/L with a correspondingly low serum osmolality of
253 mOsm/kg, low creatinine (44.2 µmol/L [0.5 mg/dL]),
low blood urea nitrogen (BUN; 3.9 mmol/L [11 mg/dL]) and
low uric acid (125 µmol/L [2.1 mg/dL]; Table 3). Corre-
spondingly, her urinary osmolality was high at 599 mOsm/
kg and urinary [Na+] was high at 99 mmol/L.
Her physician determined that her hyponatremia was
most likely being caused by SIADH. To normalize her serum
[Na+], she was admitted to the ward and fluid restriction
(1.2 L/day) was initiated. The following day, the patient
experienced ongoing motor convulsions, which were be-
lieved to be due to a focal status epilepticus so had to be
transferred to the intensive care unit (ICU). After she
arrived at the ICU, it was discovered that her serum [Na+]
had not increased as expected but had in fact dropped
further to 116 mmol/L (Figure 2)—this drop was therefore
very likely to be the reason for her clinical deterioration.
Given the severity of her symptoms, treatment with hy-
pertonic (3% NaCl) saline was commenced immediately.
Within <24 h, sodium levels rose to 123 mmol/L. Hence,
treatment with hypertonic saline was stopped and re-
placed with the oral vasopressin V2 receptor antagonist
tolvaptan 15 mg/day (Figure 2). This resulted in a further
increase in serum [Na+] with the patient exhibiting a rapid
and marked clinical improvement, which allowed her to
be discharged from the ICU 1 day later. Further work-up of
the patient’s initial feverish presentation revealed a
Table 3. Case 1: physical and laboratory data at scheduled check-up
Investigation Reading Investigation Reading
Physical examination
Weight (kg) 58 Blood pressure (mmHg) 115/75
Heart rate (b.p.m.) 93 Temperature (°C) 38.4
SpO2 (%) 98
Laboratory data
Serum [Na+] (mmol/L) 123 Uric acid (µmol/L) 125
Serum osmolality
(mOsm/kg)
253 Urinary osmolality
(mOsm/kg)
599
Serum [K+] (mmol/L) 3.2 Urinary [Na+] (mmol/L) 99
Creatinine (µmol/L) 44.2 Urinary [K+] (mmol/L) 39
Urea (mg/dL) 24
i4 M. Laville et al.
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pneumonia, which was treated successfully with anti-
biotics. It subsequently was suspected that the patient’s
SIADH had, in fact, been caused by the underlying pneu-
monia rather than her medulloblastoma as was initially
assumed. Hence, tolvaptan administration was discontin-
ued 5 days later when the patient’s serum [Na+] had nor-
malized at 137 mmol/L. The patient was discharged from
hospital by Day 13 and her serum [Na+] has remained
normal since the resolution of the pneumonia, without
the need for further tolvaptan administration.
Discussion
When a patient presents with hyponatremia, there is a
need to make a careful assessment of the volume status
of the patient. Although it is relatively simple to detect hy-
pervolemic patients through clinical signs, as they will
show signs of edema etc., it is less straightforward to
make a distinction between hypovolemic and euvolemic
patients, especially in the elderly (Table 4) [24]. It is there-
fore important to perform a thorough clinical assessment.
In addition, further diagnostic tests are key to making the
right diagnosis. The latter point is important because,
although SIADH was first described over 50 years ago [25],
the condition continues to be under-diagnosed by phys-
icians, often as a result of a failure to order sufficient diag-
nostic tests [4].
SIADH is a diagnosis of exclusion; the essential criteria
for making a diagnosis of SIADH are listed in Table 1 [15,
26]. A very simple and straightforward diagnostic algor-
ithm for hyponatremia is shown in Figure 3.
Moderate hyponatremia, like in our case report, is a
common finding in hospitalized patients, and SIADH ac-
counts for over a third of these cases. To treat such
patients properly, it is crucial to understand that hypona-
tremia is always the consequence of water excess and
never a matter of sodium loss. Thus, the aim of our treat-
ment must be the elimination of water (electrolyte-free
water clearance) rather than the supplementation of salt.
It is only in life-threatening situations, where cerebral
edema and subsequent herniation have to be suspected,
when treatment with hypertonic saline is recommended.
Otherwise, fluid restriction is the classical therapy for eu-
volemic hyponatremia. The simple logic behind that is by
restricting the patient’s fluid intake, the kidney is forced to
excrete the highly concentrated urine it already produces
anyway, due to inappropriate vasopressin action. Conse-
quently, serum [Na+] will tend to rise. However, this in-
crease is usually subtle, and hyponatremia needs several
days to subside. It is of importance to understand that the
degree of fluid restriction varies with the urinary tonicity,
i.e. the concentration of osmotically active electrolytes. To
excrete electrolyte-free water, urinary sodium plus urinary
potassium must be less than serum [Na+]. Consequently,
urinary potassium should also be regularly measured as
well as urinary [Na+]; this allows electrolyte-free water
clearance (CeH2O) to be calculated using the following
formula:
Electrolyte-freewater
clearance(CeH2O)
¼Urineoutput 1Na
þ
Urine+K
þ
Urine
NaþSerum
 
Using this formula, the calculations show that, for the
next litre of urine excreted, the patient’s electrolyte-free
water clearance would be −122 mL, i.e. she would have an
Table 4. Matrix for the differential diagnosis of the underlying etiology of
hyponatremia
Urine [Na+]
(<20 mmol/L)
Urine [Na+]
(>40 mmol/L)
Hypovolemia (dry
tongue, decreased
CVP, decreased urea,
decreased pulse,
decreased BP)
Vomiting, diarrhea,
skin losses, burns
Diuretics, Addison’s,
cerebral salt-wasting
syndrome, salt-losing
nephropathy
Euvolemia Hypothyroidism
Any cause + hypotonic
fluids
SIADH Glucocorticoid
deficiency Drugs
Hypervolemia
(edema, ascites, LVF,
increased JVP,
increased CVP)
CHF, cirrhosis
Nephrotic syndrome
Renal failure, any
cause + diuretics
BP, blood pressure; CHF, congestive heart failure; CVP, central venous
pressure; LVF, left ventricular failure; JVP, jugular venous pressure; SIADH,
syndrome of inappropriate secretion of antidiuretic hormone.
Diagnosis of the underlying etiology of the hyponatremia using this system
relies on an accurate assessment of the patient’s volume status and
measurement of urinary [Na+].
Adapted from Thompson et al. [24].
Figure 2: Case 1: treatment response and patient progress. SIADH, syndrome of inappropriate secretion of antidiuretic hormone.
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increase in free water rather than an excretion:
CeH2O= 1000mL 1138123
 
¼122mL
If you also take into account the intake (1.2 L) and the in-
sensible losses (800 mL), the free water balance is calcu-
lated as follows:
Freewater
balance
¼1200mLð122mLÞ800mL= 522mL
Hence, despite the prescribed fluid restriction, fluid
accumulation continued leading to further aggravation of
hyponatremia. For bedside purposes, the ratio of urinary
and serum electrolytes (see below) taken from the above
formula is a handy tool allowing for choosing the right
therapy, as well as for making a rough estimation on the
severity of the situation [27]. In this ratio, the numerator is
a surrogate for the urinary tonicity, whereas the denomi-
nator is a surrogate for serum tonicity. To remove free
water, the tonicity of the urine would need to be below
that of the serum, i.e. the ratio should be <1.0. When the
ratio is >1.0 (as was the case in this patient), serum [Na+]
is being lowered because of free water being retained.
Thus, the patient is at direct risk and immediate thera-
peutic action is mandatory. In addition, the fluid restric-
tion in our patient is likely to be ineffective (Table 5).
Urine toserumelectrolyte ratio
NaþUrineþKþUrine
NaþSerum
.1 !
TheCeH2O isnegative, and there
isnoexcretionof freewater;
hyponatremiawill getworse
Although it is possible that a more strict fluid restriction
of 500 mL/day may have proved more successful, it should
be borne in mind that patients with SIADH not only tend
to have a high level of vasopressin but they are also
thirsty, which contributes to their condition. In fact, it has
been shown that patients with SIADH have a downward
resetting of their osmotic threshold for thirst [28]. There-
fore, putting a patient with SIADH onto 500 mL/day fluid
restriction on a chronic basis is not an ideal solution and is
likely to incur problems with compliance. In such cases,
alternative approaches involving an increase in solute
intake or a treatment that inhibits vasopressin action on
the collecting duct, thereby enhancing free water
excretion, should be considered.
Case 2: 47-year-old man with possible anaplastic
oligoastrocytoma recurrence
V. Burst
A 47-year-old man was transferred from a secondary hospi-
tal to a university hospital following suspicious magnetic
resonance imaging (MRI) findings, which suggested a recur-
rence of his known anaplastic oligoastrocytoma and intra-
cerebral bleeding (Figure 4). The tumor (classified as WHO
grade III) had been resected 3 years previously but the
patient had subsequently developed a subdural hygroma.
Following several unsuccessful attempts to surgically
resolve the hygroma, he had received a subdural-peritoneal
Figure 3: Diagnostic algorithm for hyponatremia. BUN, blood urea nitrogen; CHF, chronic heart failure; SIADH, syndrome of inappropriate secretion of
antidiuretic hormone; TSH, thyroid-stimulating hormone.
Table 5. Recommendations for fluid restriction
NaUrineþKUrine
NaSerum
Fluid restriction
>1.0 0 mL
0.5–1.0 <500 mL
<0.5 <1 L
These recommendations assume that urinary sodium and potassium
losses are replaced that a patient has an average body surface area of
1.73 m2 and eats a normal diet, and is calculated for the period during
which the next 1 L of urine is excreted.
Adapted from Furst et al. [27].
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shunt, which had proved successful. The patient was also
coinfected with HIV and chronic hepatitis C, and had a
history of alcohol abuse. He was receiving chronic treatment
with antiretrovirals, carbamazepine and neuroleptics.
Following admission, the patient’s clinical picture deterio-
rated over the course of a few days, and a steady increase in
intracranial pressure mandated surgical intervention. Eight
days after surgery, the patient lost consciousness; he was
diagnosed with acute hyponatremia with his serum [Na+]
having dropped to 116 mmol/L from a reading of 134
mmol/L just 32 h previously. The patient was therefore
rushed to the ICU where hypertonic saline was adminis-
tered, which led to an improvement in his clinical state.
Unfortunately, his serum [Na+] rose from 116 to 129
mmol/L within 16 h, which is considered overcorrection.
Subsequently, collected urinary specimens revealed an ex-
tremely high urinary [Na+] of 222 mmol/L. This high
urinary sodium output was found to have mirrored the
high sodium intake caused by the administration of hyper-
tonic saline. Several subsequent attempts to withdraw the
hypertonic saline resulted in dramatic drops in serum
[Na+] (e.g. falls from 133 to 119 mmol/L were observed in
24 h) thereby necessitating its continuation.
Based on the assumption that SIADH was the most
likely cause of the hyponatremia, tolvaptan was initiated
at a dose of 15 mg/day on Day 5 after prior discontinu-
ation of his saline infusion (Figure 5). This resulted in an in-
crease in serum [Na+] from 120 to 130 mmol/L in 24 h and
the patient reported feeling well. He was subsequently
transferred from the ICU to the neurosurgery ward 1 day
later and was kept on tolvaptan without adverse effects.
The patient was discharged from the hospital 8 days later.
A recent attempt to withdraw the drug resulted in an ag-
gravation of the hyponatremia; therefore, the patient is
currently receiving chronic therapy with tolvaptan.
Discussion
When considering the management of hyponatremia, the
benefits of treatment must be balanced against the
potential risks. A rapid fall in serum osmolality, mirrored
by a decline of serum sodium, results in a shift of water
from the extracellular to the intracellular compartment. In
response, many if not all cells of the body are able to
undergo a process of active adaptation—accomplished by
the extrusion of intracellular organic osmolytes—in order
to induce water loss and restore cell volume [29]. However,
if the serum [Na+] decreases more rapidly than the brain
can adapt to it, then cerebral edema occurs resulting in an
increase in intracranial pressure and subsequent serious
complications [30]. Consequently, it is important that symp-
tomatic acute hyponatremia is treated urgently.
Conversely, a rapid correction of serum [Na+] in cases of
chronic hyponatremia has the potential to do more harm
than good through possible overcorrection. Although the
Figure 4: Case 2: magnetic resonance imaging suggesting a recurrence of
his known anaplastic oligoastrocytoma and intracerebral bleeding.
Figure 5: Case 2: treatment response and patient progress. ICU, intensive care unit.
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brain adapts in response to hyponatremia to protect itself
from cerebral edema, this same adaptation also makes it
vulnerable to injury if serum [Na+] is normalized too
rapidly, probably due to shrinkage of solute-depleted
brain cells. This shrinkage leads to demyelination of
pontine and extrapontine neurons and may result in
neurological dysfunction, including seizures, coma and
even death [31].
The consequences of overly rapid correction (>12
mmol/L/day) were demonstrated in an analysis by Sterns
et al. of post-therapeutic neurological complications in 56
patients treated for severe hyponatremia (serum [Na+]
≤105 mmol/L) [32]. Ten patients displayed permanent
neurological sequelae and four had transient neurological
complications that emerged after serum [Na+] was in-
creased to >120 mmol/L. Analyses of variables determin-
ing outcome in these patients showed that neurological
sequelae after the treatment of severe chronic hyponatre-
mia were associated with increases in sodium concen-
tration that were >12 mmol/L over the first 24 h and >18
mmol/L over the first 48 h of therapy. Furthermore, the
chronicity of hyponatremia was significantly associated
with complications (P < 0.01 versus acute hyponatremia).
It is now generally accepted that the rate of serum [Na+]
correction in chronic hyponatremia should be limited to
<10–12 mmol/L in 24 h or to <18 mmol/L in 48 h [26].
However, it should be taken into consideration that patients
with alcoholism, as was the case in our patient, may be
especially susceptible to osmotic demyelination syndrome
(ODS) [33]. Thus, given the risk of overshooting maximal
recommended increases, it is perhaps best to aim for cor-
rection by ∼8 mmol/L/day in these patients [26].
Despite overcorrection with hypertonic saline in this
case (serum [Na+] increased 13 mmol/L in 16 h), the
patient did not develop any neurological issues. Although
there have been no reported cases of osmotic demyelina-
tion associated with the use of vaptans, to date, there is a
need for careful monitoring of serum [Na+] responses
during correction of hyponatremia as per the recommen-
dations in the product licence.
Case 3: 81-year-old woman presenting with
mental confusion
A. Peri
An 81-year-old Caucasian woman was brought in to the
emergency department of the University Hospital in Flor-
ence suffering from mental confusion. Her past medical
history showed that she had hypertension, peripheral
atheromatosis, and had experienced a previous transitory
ischemic attack. Over the last year, she complained of an
inability to perform normal cognitive functions and had
experienced frequent falls. Her existing medications in-
cluded ramipril 2.5 mg/day, lansoprazole 30 mg/day and
acetylsalicylic acid 100 mg/day.
The patient’s blood pressure was 170/100 mmHg and
heart rate 70 b.p.m.; routine laboratory testing revealed
that her serum [Na+] was only 120 mmol/L (Table 6). At
this point, her son recalled that the patient’s serum [Na+]
had been frequently documented below the normal range
over the last year.
No further diagnostic tests were performed at this stage
and the patient was administered intravenous isotonic
saline in the emergency department in order to correct
her low serum [Na+]. Unfortunately, there was no change
in serum [Na+] and the patient’s condition showed no im-
provement.
The patient was subsequently admitted to the internal
medicine unit where she was given a comprehensive diag-
nostic work-up (Table 6). The patient was shown to be
clinically euvolemic. A cranial computed tomography (CT)
scan showed no signs of intracranial bleeding or subcorti-
cal ischemic encephalopathy, but a chest X-ray revealed
that she had pneumonia (Figure 6). Consequently, the
patient was diagnosed with hyponatremia secondary to
SIADH caused by underlying pulmonary disease.
The patient was treated with hypertonic saline (3%
NaCl); her existing lansoprazole was stopped following a
negative gastroduodenoscopy and acetylsalicylic acid re-
placed by ticlopidine 250 mg/day. For her pneumonia, she
was prescribed antibiotics (levofloxacin 500 mg/day orally
and ceftriaxone 2 g/day intramuscularly).
Table 6. Case 3: laboratory values at admission and diagnostic work-up
Laboratory measurement Results Normal range
At admission
Glucose (mmol/L) 5.16 3.6–6.3
Serum [Na+] (mmol/L) 120 135–146
Serum urea (g/L) 0.41 0.1–0.5
Hemoglobin (g/L) 109 120–160
Hematocrit (proportion of 1.0) 0.32 0.36–0.46
Serum creatinine (μmol/L) 56.6 35.4–79.6
Serum uric acid (μmol/L) 131 208–387
Serum [K+] (mmol/L) 4.1 3.5–5.3
Diagnostic work-up
TSH (miU/L) 1.18 0.25–3.50
Free T4 (pmol/L) 14.8 10.3–19.4
Serum [Na+] (mmol/L)a 121 135–146
Urinary [K+] (mmol/L) 48 25–125
Urinary [Na+] (mmol/L) 89 25–250
Triglycerides (mmol/L) 0.71 0.57–1.92
Cholesterol (mmol/L) 4.45 4.14–5.70
Total protein (g/L) 0.062 0.06–0.086
Cortisol (nmol/L) 603 160–690
Plasma osmolality (mOsm/kg) 259 285–295
Urine osmolality (mOsm/kg) 307 300–1100
aFollowing isotonic saline infusion.
Figure 6: Case 3: pneumonia diagnosed via chest X-ray.
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Following 24 h, the patient’s serum [Na+] rose to 127
mmol/L, at which point her infusion was stopped. Fluid re-
striction was then considered. However, calculations
based on the patient’s ratio of electrolytes in the urine
and serum (according to the formula: urinary [Na+] +
urinary [K+]/serum [Na+]) [27] gave a result >1.0, which
implied that the free water clearance of the patient was
nil. Thus, fluid restriction was unlikely to improve serum
[Na+] in this patient; therefore, therapy with tolvaptan 15
mg/day was started. This raised her serum [Na+] to 132
mmol/L after 24 h and marked clinical improvement was
observed on the second day, when her serum [Na+] was
138 mmol/L. The patient was eventually discharged after
6 days on tolvaptan.
At a follow-up assessment 1 week after discharge, the
patient’s sodium levels remained within the normal range,
her clinical condition was good and a further chest X-ray
showed no evident radiological signs of pneumonia. Tol-
vaptan treatment was therefore stopped at a serum [Na+]
of 141 mmol/L. Serum [Na+] remained within the normal
range at follow-up.
Discussion
Chronic hyponatremia is associated with increased
patient morbidity. A four-fold increase in the incidence of
falls has been reported by Renneboog et al. [10] in
patients with apparently ‘asymptomatic’ chronic hypona-
tremia (mean serum [Na+] 126 ± 5 mmol/L) admitted to
the emergency department, compared with matched con-
trols with normal serum [Na+] (21.3 versus 5.3%). Further
analyses revealed that these falls may possibly be the
result of marked gait and attention impairments in these
patients [10]. Consequently, it is logical to deduce that
this patient’s neurological symptoms and a history of falls
over the past year are linked to her chronic hyponatremia
rather than to another underlying disease. Taking steps to
correct her persistent hyponatremia may therefore help
reverse these symptoms.
In practice, it may be a tempting diagnostic procedure
to administer isotonic saline to all patients with low
serum [Na+] before the fluid volume status of the patient
has been determined and monitor the response to
therapy. However, although isotonic saline can be used to
treat hypovolemic hyponatremia, it is not an appropriate
treatment in a patient with euvolemic hyponatremia and
may even exacerbate problems in such patients. It is,
therefore, important to perform sufficient tests in order to
identify the underlying etiology of hyponatremia. Asses-
sing the patient’s serum and urinary osmolality, fluid
volume status and urinary [Na+] plays a pivotal role in the
differential diagnosis of hyponatremia (Table 1). In this
case, the patient was found to be clinically euvolemic and
diagnosed with SIADH.
The etiology of SIADH can be classified into five major
categories including malignancies, pulmonary disorders,
central nervous system disorders, drug-related and a fifth
category that includes idiopathic SIADH and other causes
(Table 7) [15, 26]. Of these, lung cancer, pulmonary infec-
tions, CNS infections, stroke, antiepileptics, antidepress-
ants and idiopathic origins are the most common causes
of SIADH [34]. Investigating the etiology of SIADH is
important because if the underlying cause is not
managed then the hyponatremia could return. It is also
important that an underlying malignancy, particularly of
the lung, is not missed.
Investigations revealed that the patient had normal
thyroid and adrenal functions, thereby ruling out glucocor-
ticoid deficiency and hypothyroidism as possible causes.
Her existing medications [an angiotensin-converting
enzyme (ACE) inhibitor, a proton-pump inhibitor and acet-
ylsalicylic acid] suggested that drug-induced hyponatre-
mia could be a possible candidate for the underlying
cause (Table 8). However, ACE inhibitors and proton-pump
inhibitors are relatively rare causes of hyponatremia [35]
and, as the patient had been taking her medications for a
long time without ill effect, it was probable that her hypo-
natremia was being caused by something else.
Table 7. Causes of SIADH [26]
Malignancy Pulmonary/mediastinal (bronchogenic carcinoma,
mesothelioma, thymoma)
Non-chest (duodenal carcinoma, pancreatic carcinoma,
ureteral/prostate carcinoma, uterine carcinoma,
nasopharyngeal carcinoma, leukemia)
CNS
disorders
Mass lesions (tumors, brain abscesses, subdural
hematoma)
Inflammatory diseases (encephalitis, meningitis,
systemic lupus, acute intermittent porphyria, multiple
sclerosis)
Degenerative/demyelinative diseases (Guillain–Barré
syndrome, spinal cord lesions)
Miscellaneous (subarachnoid hemorrhage, head trauma,
acute psychosis, delirium tremens, pituitary stalk section,
transsphenoidal adenomectomy, hydrocephalus)
Drugs Stimulated vasopressin release
Direct renal effects and/or potentiation of vasopressin
antidiuretic effects
Mixed or uncertain actions
Pulmonary
diseases
Infections (tuberculosis, acute bacterial and viral
pneumonia, aspergillosis, empyema)
Mechanical/ventilatory (acute respiratory failure, COPD,
positive pressure ventilation)
Other AIDS and ARC
Prolonged strenuous exercise (marathon, triathlon,
ultramarathon, hot-weather hiking)
Prolonged nausea and vomiting (e.g. with
chemotherapy)
Senile atrophy
Idiopathic
ARC, AIDS-related complex; COPD, chronic obstructive pulmonary disease.
Adapted from Verbalis et al. [26].
Table 8. Causes and underlying mechanisms of drug-induced
hyponatremia [35]
Drugs affecting sodium
and water homeostasis
Diuretics
Drugs affecting water
homeostasis
Antidepressants, antipsychotic drugs, opioids,
antiepileptic drugs, anticancer agents
Potentiation of
vasopressin effect
Antiepileptic drugs, antidiabetic drugs
anticancer agents, non-steroidal anti-
inflammatory drugs
Reset osmostat Antidepressants, antiepileptic drugs
Rare causes of drug-
induced hyponatremia
Antihypertensive agents, immune
globulin (intravenous), 3,4-
methylenedioxymethamphetamine (ecstasy),
antibiotics, antiarrhythmic, theophylline,
proton pump inhibitors, bromocriptine,
terlipressin, duloxetine, fluorescein
angiography, bupropion
Adapted from Liamis et al. [35].
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Following a chest X-ray, it was confirmed that the
patient’s SIADH was most likely being caused by under-
lying pneumonia. At this stage, she was prescribed anti-
biotics for her pulmonary infection. Rather than simply
wait for the infection to resolve, and her hyponatremia to
subsequently normalize, it is important to realize the
benefits of immediately treating hyponatremia. It was the
patient’s hyponatremia rather than the underlying
disease that was keeping her hospitalized by making her
confused and prone to falls; therefore, direct treatment of
her hyponatremia would hopefully result in her being dis-
charged earlier, as well as reducing the risk of rehospitali-
zation. She was, therefore, also treated initially with
hypertonic saline (3% NaCl) 20 mL/h (according to the
Adrogué and Madias formula) [31]:
Formula for the calculation of the infusion rate of saline
solution
Change in serum Naþ
after 1 L of any infusate
¼ Infusate [Na
þ] Serum [Naþ]
Total bodywaterþ 1
If potassium has been added into the infusate then the
calculation should bear this in mind, i.e.
Change in serumNaþ
after 1 L of any infusate
¼
ðInfusate½Naþ þ ½KþÞ
ðSerum½Naþ þ ½KþÞ
Totalbodywaterþ1
The infusion was stopped after 24 h with her serum
[Na+] raised to 127 mmol/L. At this stage, fluid restric-
tion—often the standard of care in patients with asymp-
tomatic hyponatremia secondary to SIADH—was
considered. However, acknowledging the difficulties
patients often have in maintaining fluid restriction, its
slowness in increasing serum [Na+] and the predicted
absence of free water excretion, it was decided to
further treat her with the vasopressin V2 receptor antag-
onist tolvaptan at 15 mg/day taken orally. This produced
a rise in serum [Na+] to 132 mmol/L after 24 h; the
patient had marked clinical improvement on the second
day (serum [Na+] 138 mmol/L), and she was discharged
after 6 days on tolvaptan.
Tolvaptan treatment was stopped at a serum [Na+] of
141 mmol/L after a follow-up assessment 1 week later. The
patient’s sodium levels remained within normal ranges, her
clinical condition was good and there were no evident
radiological signs of pneumonia at a control chest X-ray.
Case 4: 74-year-old man presenting with a cough
and hemoptysis
A. Peri
A 74-year-old Caucasian man presented with a cough and
hemoptysis, with which he had been suffering for the last
3 months. Although he had previously been prescribed
antibiotics, they had proved ineffective. He was a long-
term heavy smoker (smoking 40 cigarettes per day over
the last 40 years); although his medical history included
surgery for an inguinal hernia in 1987 and a diagnosis of
benign prostatic hyperplasia in 2009, he was not receiving
any chronic medications. The patient also complained of a
slightly elevated temperature and asthenia. For this
reason, his physician sent him to the emergency
department of the University Hospital in Florence from
which he was referred to the pneumology unit.
At the time of admission, the patient’s laboratory find-
ings showed a normal serum [Na+] of 141 mmol/L (Table 9).
A few days following admission, the patient started com-
plaining of chest pain for which he was prescribed an
opiate (oxycodone 5 mg o.d.) together with paracetamol
325 mg t.i.d.; at this stage, he was also receiving methyl-
prednisolone 16 mg o.d., lansoprazole 30 mg o.d. and tra-
nexamic acid 500 mg b.i.d. for his hemoptysis.
Over the following 15 days, the patient experienced a
progressive reduction in serum [Na+] down to 123 mmol/L.
His plasma osmolality was low (267 mOsm/kg), urinary os-
molality was 646 mOsm/kg and urinary [Na+] 130 mmol/L;
other measurements such as uric acid and potassium
concentration were in the normal range (Table 9). The
patient was apparently asymptomatic, he was clinically
euvolemic and his profile fitted that of a person with hypo-
natremia secondary to SIADH (Table 1)—the most
common cause of euvolemic hyponatremia [36].
A CT scan revealed a large mediastinal mass, which
turned out to be small-cell lung carcinoma (SCLC)
(Figure 7A). Fluid restriction was initiated in an effort to
resolve the hyponatremia; this resulted in an initial in-
crease in serum [Na+], however, the concentration
remained below the normal range of 135 mmol/L after
15 days. Because the patient required chemotherapy with
etoposide and carboplatin—drugs that may also cause
SIADH—it was important to fully resolve the patient’s hy-
ponatremia before chemotherapy could be initiated. Fluid
restriction was therefore discontinued and the oral vaso-
pressin antagonist tolvaptan 15 mg/day initiated, thus
making this the first person to be treated with tolvaptan in
Italy.
Within 24 h, the patient’s serum [Na+] had normalized
allowing the prompt initiation of chemotherapy. However,
over the next month the patient’s serum [Na+] continued
to steadily increase to 147 mmol/L at which point tolvap-
tan therapy was stopped (the only case in our clinic where
overcorrection with tolvaptan has been observed, so far).
Sodium concentrations then promptly returned to normal
concentrations (Figure 8).
After 3 months of chemotherapy, a CT scan showed a
large reduction in a tumor mass (Figure 7B) and the
patient’s serum [Na+] remained stable. The patient was
subsequently regularly monitored; serum [Na+] remained
within the normal range and the patient reported a rather
Table 9. Case 4: laboratory data at admission and in-patient assessments
Investigation Reading Investigation Reading
At admission
Serum [Na+] (mmol/L) 141 Glucose (mmol/L) 5.6
Serum [K+] (mmol/L) 4.1 Cholesterol (mmol/L) 4.3
Creatinine (µmol/L) 80.4 Triglycerides (mmol/L) 1.2
Urea (mg/dL) 26 Total proteins (g/L) 0.06
In-patient assessments
Plasma osmolality
(mOsm/kg)
267 Serum [K+] (mmol/L) 3.9
Urinary osmolality
(mOsm/kg)
646 Glucose (mmol/L) 4.6
Urinary [Na+] (mmol/L) 130 Urea (mg/dL) 22
TSH (miU/L) 0.96 Creatinine (µmol/L) 64.5
fT4 (pmol/L) 18.9 Uric acid (µmol/L) 238
fT4, free thyroxine; TSH, thyroid-stimulating hormone.
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good quality of life at follow-up. Unfortunately, as ex-
pected, disease progression occurred after 8 months of
clinical remission and the patient passed away ∼1 year
after the initial diagnosis.
Discussion
Hyponatremia is a common feature in oncology practice
[37], occurring most frequently in patients with SCLC [38].
A quarter of all patients with SCLC were identified as
having sodium [Na+] of <136 mmol/L in a large analysis of
nine consecutive clinical trials in Denmark and Sweden
(n = 1684) [39]. Comparable rates (25–44%) were also ob-
served in smaller SCLC cohort analyses using a similar cut-
off [40–42].
SIADH is the most common cause of hyponatremia,
with higher rates found in patients with SCLC than with
other malignancies [43, 44]. Four different patterns of va-
sopressin secretion have been identified in patients with
SIADH (Figure 9):
(i) Type A is characterized by an unregulated, erratic,
secretion independent of the prevailing plasma os-
molality.
(ii) Type B is characterized by an elevated basal secretion
of vasopressin, despite normal regulation by osmolality.
(iii) Type C is characterized by a ‘reset osmostat’ system,
whereby vasopressin is secreted at an abnormally low
threshold of plasma osmolality but otherwise displays
a normal response to relative changes in osmolality.
(iv) Type D is characterized by undetectable vasopressin
levels (some of these patients may have gain-of-func-
tion mutations in the vasopressin V2 receptor) [15,
45, 46].
Type A vasopressin secretion tends to be usually found in
paraneoplastic SIADH [47]. It has been proposed that the
term ‘syndrome of inappropriate antidiuresis’ (SIAD) may
be more suitable for this condition as not all patients with
Figure 7: Case 4: results of CT scans. CT scan taken at (A) initial presentation and (B) after 3 months’ therapy with etoposide and carboplatin.
Figure 8: Case 4: serum [Na+] response to treatment.
Hyponatremia secondary to the syndrome i11
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/6/suppl_1/i1/398153 by U
N
IVER
SITA D
I FIR
EN
ZE D
IPAR
TIM
EN
TO
 D
I PED
IATR
IA user on 23 N
ovem
ber 2018
SIADH have elevated levels of vasopressin [15]. Many of
these patients respond to the administration of vasopressin
receptor antagonists with an aquaresis, suggesting that
they have low levels of inappropriate vasopressin secretion
despite the difficulty measuring such low levels. An excep-
tion is a patient group with gain-of-function mutations in
the vasopressin V2 receptor—identified in infants with clini-
cal and laboratory features consistent with the presence of
SIADH but with undetectable vasopressin levels—who do
not appear to respond to the administration of vasopressin
receptor antagonists [45, 48]. Although this mutation
appears to be a rare cause of hyponatremia at this time,
the term SIAD would comprise these patients.
Although SCLC is a known cause of SIADH, it must also be
borne in mind that the patient in this case would have had
carcinoma at the time of admission, yet his serum [Na+]
had been normal. However, opiates are another potential
cause of SIADH and the patient’s decline in serum [Na+]
began with the administration of the opiate oxycodone for
his chest pain. Consequently, it is possible that the patient
initially had a low level of vasopressin, which then randomly
increased and, together with the opiate, caused the decline
in serum [Na+]. It is therefore important to continuously
monitor sodium levels carefully in such patients as vaso-
pressin levels can increase randomly.
Although this patient was treated with fluid restriction, it
is nowadays likely that therapy with an oral vasopressin V2
receptor antagonist, i.e. tolvaptan, would be initiated
earlier rather than after fluid restriction. The patient re-
quired urgent chemotherapy so his hyponatremia needed
to be corrected as quickly as possible so that chemotherapy
could be administered; however, fluid restriction usually
takes several days before a significant increase in serum
[Na+] is achieved, no doubt exacerbated by the fact that
patient compliance with fluid restriction is often poor [38].
Tolvaptan acts by antagonizing the effects of endogen-
ous vasopressin at the V2 receptors in the renal collecting
duct. This causes an increase in urine water excretion, re-
sulting in an increase in free water clearance (aquaresis),
a decrease in urine osmolality and a resultant increase in
serum [Na+]. Urine excretion of sodium and potassium is
not significantly affected. The effects of tolvaptan on this
patient are shown in Figure 10.
Serum [Na+] normalized within 24 h following adminis-
tration of tolvaptan, thereby allowing the prompt initiation
of chemotherapy. In the only case of its kind observed in
our clinic so far, the patient’s sodium level continued to
steadily increase above normal levels, reaching a peak of
147 mmol/L ∼25 days after initial drug administration
(Figure 8). This necessitated the cessation of tolvaptan
therapy upon which serum [Na+] returned to normal
levels. This overcorrection was likely influenced by the
patient continuing to limit his fluid intake following the
initiation of tolvaptan despite feeling thirsty. Conse-
quently, it is important to advise patients that they can,
and should, drink fluid in response to thirst during tolvap-
tan therapy.
Case 5: 51-year-old man with subarachnoid
hemorrhage
J. G. Verbalis
A 51-year-old man previously in good health except for
hyperlipidemia was found unconscious in his bathroom.
After awakening, he complained of a severe headache. A
CT scan of the head showed a subarachnoid hemorrhage
(SAH) with blood in the cisterns bilaterally. On transfer to a
university hospital, he was awake and oriented with no
focal neurological deficits but was noted to be drowsy and
lethargic with intermittent nausea and vomiting. A phys-
ical exam was unremarkable except for a blood pressure
of 149/76 mmHg, and the patient was felt to be clinically
euvolemic. Admission laboratory values were all within
normal limits, including electrolytes with a serum [Na+] of
139 mmol/L.
The patient was admitted to the neurosurgical ICU,
where his blood pressure was controlled with labetalol and
hydralazine drips. A cerebral angiogram revealed an
anterior communicating artery aneurysm, which was suc-
cessfully occluded by insertion of a coil by interventional
neuroradiology. He was started on nimodipine for vasos-
pasm prophylaxis and diphenylhydantoin for seizure pro-
phylaxis. An external ventricular drain was placed to control
intracranial pressure. Triple-H therapy (i.e. the induction of
hypertension, hypervolemia and hemodilution to decrease
the risk of vasospasm [49]) was begun for the SAH, includ-
ing volume expansion via intravenous fluid administration
with isotonic (0.9%) saline at rates varying between 125
and 175 mL/h. Total fluid intake ranged between 5 and 7 L/
24 h over the first week of hospitalization.
The patient stabilized neurologically; but by Day 4, his
serum [Na+] was noted to be intermittently low and the
patient was started on NaCl tablets 8 g daily in divided
doses (Figure 11). Despite this therapy, sodium levels con-
tinued to fall to the 125–127 mmol/L range and the patient
became confused and lethargic. The oral NaCl was sup-
plemented with an intravenous infusion of hypertonic (3%)
NaCl, initially at 50 mL/h then increasing to 70 mL/h. By
Day 8, the endocrinology service was consulted because of
persistent hyponatremia and worsening neurological
status despite aggressive NaCl administration, which by
that time totalled as high as 62 g/day.
On evaluation by the endocrinology department, the
patient was clinically euvolemic. Serum [Na+] was in the
range of 125–126 mmol/L with a plasma osmolality of 266
mOsm/kg and urine osmolalities ranging from 283 to 369
Figure 9: Patterns of plasma vasopressin levels where compared with
plasma sodium levels in patients with SIADH [15]. Type A is characterized
by unregulated secretion of vasopressin, type B by elevated basal secretion
of vasopressin despite normal regulation by osmolality, type C by a ‘reset
osmostat’ and type D by undetectable vasopressin. The shaded area
represents normal values of plasma vasopressin.
Adapted from Ellison and Berl [15].
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mOsm/kg. Urine [Na+] was noted to be 83 mmol/L with
urine [K+] = 8.5 mmol/L prior to the start of oral NaCl
tablets, and increased to 162 mmol/Lwith urine [K+] = 12.1
mmol/L following oral NaCl therapy. BUN was 2.1 mmol/L
(6 mg/dL) and creatinine 53 µmol/L (0.6 mg/dL), with
normal glucose levels. Thyroid function was normal: free T4
was 12.1 pmol/l (0.94 ng/dL) (normal range 0.58–1.64) and
thyroid-stimulating hormone was 2.96 µIU/mL (normal
range 0.35–5.5). A random measurement of cortisol levels
showed an elevation at 792 nmol/L (28.7 µg/dL). Serum
uric acid was low at 155 µmol/L (2.6 mg/dL) (normal range
208–387). Analysis of the intakes and outputs showed that
the patient had been in a positive fluid balance each day
over the first week of hospitalization.
Based on the patient’s physical exam, laboratory values
and clinical course, he was assessed to have euvolemic
hyponatremia that was unresponsive to NaCl adminis-
tration, which met the criteria for a diagnosis of SIADH
(Table 1). Because the neurosurgeons would not consider
instituting fluid restriction due to the risk of vasospasm
from the SAH [49], therapy with tolvaptan was rec-
ommended at a starting dose of 15 mg/day. Although
fluid restriction was relatively contraindicated in this case,
it likely would not have been effective even if employed in
view of the high urine to plasma electrolyte ratio that
ranged from 0.73 to 1.39 (Table 5). After the first 15 mg
dose, the patient developed a negative fluid balance of
−2.5 L and his serum [Na+] increased from 126 to 132
Figure 10: Case 4: response to tolvaptan therapy. Effect of tolvaptan before and after administration on (A) diuresis (average value between Day 1 and 7
following tolvaptan; statistical analysis conducted using Student’s t-test), (B) urinary osmolality and (C) urinary [Na+].
Figure 11: Case 5: treatment summary, serial serum [Na+] measurements, and patient progress.
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mmol/L. Despite recommendations that the 3% NaCl infu-
sion be stopped once an increase in serum [Na+] of 5
mmol/L had occurred, the 3% NaCl infusion was contin-
ued. After the second 15 mg tolvaptan dose, the patient
developed a negative fluid balance of −4.2 L and his
serum [Na+] increased further to a maximum of 144
mmol/L. The 3% NaCl was subsequently discontinued and
serum [Na+] stabilized between 132 and 135 mmol/L.
After 5 days, the tolvaptan dose was increased to 30 mg/
day with normalization of serum [Na+] to 138–140 mmol/
L; the patient was discharged on this dose on Day 16. His
serum [Na+] remained normal at subsequent outpatient
follow-up, and tolvaptan was discontinued 4 weeks after
discharge without recurrence of the hyponatremia.
Discussion
Patients with acute neurological disorders, such as SAH,
represent an especially challenging group of patients with
hyponatremia. This is because the mild degrees of cer-
ebral edema produced by hyponatremia that would not
cause significant neurological symptoms in normal brains,
can worsen both symptoms and recovery from already
damaged brain tissue as a result of increased intracranial
pressure [50]. Consequently, both avoidance of hyponatre-
mia, and prompt and effective treatment of hyponatremia,
when it occurs, is a crucial aspect of management in
patients with acute neurological disorders.
The degree to which hyponatremia occurs primarily as a
result of natriuresis has remained controversial for many
years. Cerebral salt wasting (CSW) was first proposed by
Peters in 1950 [51] as an explanation for the natriuresis
and hyponatremia that sometimes accompanies intracra-
nial disease, particularly SAH, in which up to one-third of
patients often develop hyponatremia. Following the first
clinical description of SIADH in 1957 [25], such patients
were generally assumed to have hyponatremia secondary
to vasopressin hypersecretion with a secondary natriuresis
[52]. However, over the last decade, clinical and exper-
imental data have suggested that some patients with SAH
and other intracranial diseases may actually have a
primary natriuresis leading to volume contraction rather
than SIADH [53–56]; in which case, the elevated
measured plasma vasopressin levels may actually be
physiologically appropriate for the degree of volume con-
traction present. The major clinical question as to the fre-
quency of CSW as a cause of hyponatremia is dependent
on the criteria used to assess the extracellular fluid (ECF)
volume status of these patients; opponents argue that
there is insufficient evidence of true hypovolemia despite
ongoing natriuresis [57], whereas proponents argue that
the combined measures that have traditionally been used
to estimate ECF volume do in fact support the presence of
hypovolemia in many cases [58, 59].
With regard to the potential mechanisms underlying
the natriuresis, in both plasma and cerebrospinal fluid
(CSF), atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP), levels are clearly elevated in many patients
with SAH [56, 60–62] and have been found to correlate
variably with hyponatremia in patients with intracranial
diseases [56, 62, 63]. However, because SIADH is also fre-
quently associated with elevated plasma ANP and BNP
levels, this finding alone does not prove causality. Ample
precedent certainly exists for hyponatremia due to
sodium wasting with secondary antidiuresis in Addison’s
disease, as well as diuretic-induced hyponatremia. But,
characteristic of these disorders, normalization of ECF
volume with isotonic NaCl infusions restores plasma toni-
city to normal ranges by virtue of shutting off the second-
ary vasopressin secretion. If hyponatremia in patients
with SAH occurred via a similar mechanism, it should also
respond to this therapy. However, studies indicate that it
does not. Nineteen patients with SAH were treated with
large volumes of isotonic saline sufficient to maintain
plasma volume at normal or slightly elevated levels, but
despite removal of any volume stimulus to vasopressin
secretion, 32% still developed hyponatremia in associ-
ation with non-suppressed plasma vasopressin levels, an
incidence equivalent to that found in previous studies of
SAH [64]. In contrast, other studies have demonstrated
that mineralocorticoid therapy to inhibit natriuresis can
reduce the incidence of hyponatremia in patients with
SAH [65]; such results are not unique to patients with in-
tracranial diseases, since a subset of elderly patients with
SIADH have also been shown to respond favorably to
mineralocorticoid therapy [66]. Although seemingly dispa-
rate, these types of results support the existence of disor-
dered vasopressin secretion as well as a coexisting
stimulus to increased natriuresis in many such patients. It
seems most likely that SAH and other intracranial diseases
represent a mixed disorder in which some patients have
both exaggerated natriuresis and inappropriate vasopres-
sin secretion; which effect predominates in terms of the
clinical presentation will depend on their relative intensi-
ties, as well as the effects of concomitant therapy.
This case graphically illustrates the important role
played by SIADH in acute neurological disorders such as
SAH. This patient was initially assumed to have CSW as a
result of hyponatremia with an elevated urine sodium
excretion. However, the patient never actually met criteria
for a diagnosis of CSW, since volume depletion resulting
from natriuresis was never documented. In addition, ag-
gressive volume expansion as part of the triple-H therapy
typically employed in patients with SAH failed to improve
the hyponatremia; in fact, the serum [Na+] decreased in
conjunction with the large volumes of fluid typically
infused as a component of triple-H therapy. Subsequent
therapy with the vasopressin receptor antagonist tolvap-
tan produced correction of the hyponatremia as a result
of the induced aquaresis, thereby documenting vasopres-
sin-induced water retention as the major etiological factor
causing this patient’s hyponatremia.
Treatment of hyponatremia in patients with acute
neurological injury is challenging. Patients with SAH have
been shown to have worse outcomes with fluid restriction,
presumably as a result of vasospasm [54]. This has led to
the widespread use of triple-H therapy to decrease the
risk of vasospasm [49], though definitive evidence in
support of this therapy is lacking [67]. Based on these find-
ings, treatment of patients with true CSW using vaptans
would be contraindicated, since such patients are by defi-
nition hypovolemic, which is a contraindication to the use
of vaptans because of the risk of worsening volume
depletion with resulting hemodynamic instability, hypoten-
sion and, in this group of patients, increased risk of vasos-
pasm. However, the widespread employment of triple-H
therapy effectively eliminates the possibility of CSW in most
patients as a result of the volume expansion produced by
NaCl administration, whether as oral, isotonic or hypertonic
NaCl administration, or all three as in this case. When hypo-
natremia persists in the face of volume expansion, then it
can only be due to vasopressin-induced water retention,
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which was proved by the favorable response to tolvaptan in
this case. It should be remembered that the indication for
therapy with a vasopressin receptor antagonist is euvole-
mic hyponatremia due to SIADH (EU and USA) or hypervo-
lemic hyponatremia due to heart failure (USA only), not to
the underlying cause of the SIADH. Consequently, even
if this patient had a component of salt wasting due to
CSW, his clinical picture was clearly one of euvolemic hypo-
natremia from SIADH, thereby making vaptan therapy an
appropriate choice.
This case illustrates three additional important
aspects of clinical use of vaptans. First, caution must be
used when using vaptans in combination with other
therapies for the treatment of hyponatremia. Extra
caution should be employed if fluid restriction is used in
combination with vaptan therapy to ensure that dehy-
dration does not occur (patients should have access to
drinking water), and concomitant use with hypertonic
saline is not recommended in order to avoid the possi-
bility of overly rapid correction of the hyponatremia with
subsequent risk of precipitating the ODS [17]. This
patient stayed within accepted guidelines for hyponatre-
mia correction to reduce the risk of ODS [26], with a cor-
rection of 5 mmol/L in the first 24 h of therapy and 17
mmol/L in the first 48 h of therapy, but came close to ex-
ceeding these limits. If therapies are combined, in this
case because of uncertainty of whether the tolvaptan
would be effective at raising the serum [Na+], then the
serum [Na+] must be monitored frequently in order to
stop combined therapy once an acceptable response is
seen. Secondly, effective therapy of hyponatremia is
often a major determinant of patient discharge from
ICUs and hospitals. In this case, continued use of ineffec-
tive therapies such as excessive NaCl administration
would very likely have further prolonged this patient’s
hospital stay. Finally, many cases of hyponatremia are
transient and resolve following treatment of the under-
lying disease process causing the hyponatremia. SAH is a
classic example of this situation, in which the hyponatre-
mia typically resolves 2–4 weeks after the clearance of
blood products from the CSF. Outpatient monitoring of
serum [Na+], including a planned trial of drug cessation,
is required to determine whether continued therapy is
necessary. Which patients should be discharged on
vaptans to maintain normonatremia, and for how long,
therefore depends critically upon the underlying etiology
of the hyponatremia (Figure 12) [68].
Discussion and conclusions
J. G. Verbalis
As stated in the introduction to this article, among the
many reasons why the diagnosis and treatment of hypo-
natremia remains far from optimal is the heterogeneous
nature of the disorder, including a wide variety of possible
etiologies, variable symptomology and differing fluid
volume status. The five cases presented here abundantly
illustrate the marked heterogeneity in the presentations
Figure 12: Estimated probability of need for long-term treatment of SIADH depending on underlying etiology [68]. Adapted from Verbalis [68].
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of hyponatremia. As always is the case in medical practice,
therapy in each case must be individualized to the patient.
But despite their many differences, the cases presented
here also illustrate that adherence to accepted guidelines
for the diagnosis of SIADH and rational decision-making
among the available therapeutic options for treating hy-
ponatremia, importantly including the new class of vaso-
pressin receptor antagonists, can achieve desirable
outcomes in the majority of cases.
Case 1 illustrates a case of severe symptomatic hypona-
tremia with seizures who was appropriately treated with
3% NaCl followed by tolvaptan therapy to finish a con-
trolled correction of the hyponatremia. The case empha-
sizes several important points about management of
hyponatremia. First, the patient’s symptoms did not
deteriorate until her serum [Na+] decreased while on a
fluid restriction of 1.2 L/day. As discussed by Dr Burst, em-
ployment of simple calculations such as the urine to
plasma electrolyte ratio can identify patients in whom
fluid restriction is likely to be ineffective, or even danger-
ous by virtue of negative electrolyte-free water clearance,
as summarized in Table 5 [27]. Rather than assuming that
all patients with SIADH should have an initial trial of fluid
restriction, intelligent decision-making in 2013 should
employ a careful analysis of which patients are likely to
respond, and to what degree, before choosing an initial
therapy. Although it is comforting that the patient re-
sponded to sequential therapy with hypertonic saline and
tolvaptan with rapid discharge from the ICU and hospital,
it is likely that initial therapy with tolvaptan rather than
fluid restriction would have prevented the clinical deterio-
ration that required ICU transfer and 3% NaCl rescue in
the first place. This case raises the important issue of the
appropriate choice of initial therapy of patients with
SIADH; a careful assessment of the patient’s likelihood of
responding to individual therapies is clearly superior to
choosing treatments simply because they are typically
employed in such patients.
A second important point made by this case is that not
all patients with malignancies have tumor-induced hypo-
natremia. There is no question that this patient met stan-
dard criteria for SIADH as shown in Table 1, but the list of
potential etiologies of SIADH is long (Table 7), and one
must consider many possibilities in patents with malig-
nancies. The finding that this patient more likely had a
pneumonia-induced SIADH had important implications
for her long-term therapy, since it allowed discontinuation
of the tolvaptan after successful therapy of the pneumo-
nia; had this truly been tumor-associated SIADH, the
patient would likely have required more chronic therapy
for the hyponatremia (Figure 12).
Case 2 represents another common cause of SIADH,
namely both acute and chronic neurological disorders.
The case illustrates the risks of overly rapid correction
using 3% NaCl. There is no question that this is the appro-
priate therapy for patients with severe symptomatic hypo-
natremia, as in this case. However, even in the best hands
at advanced academic medical centers, overly rapid cor-
rection of hyponatremia remains a potential risk using hy-
pertonic saline [69]. However, this patient did not develop
symptoms of ODS despite overcorrection of his serum
[Na+] by 13 mmol/L over 16 h. The most likely reason is
that this was an acute hyponatremia. Studies in exper-
imental animals have shown that the brain adapts to
chronic hyponatremia by loss of solute, both as electro-
lytes and organic osmolytes. ODS is likely precipitated by
brain dehydration that has been demonstrated to occur
following correction of serum [Na+] toward normal ranges
in animal models of chronic hyponatremia. Because the
degree of osmotic brain shrinkage is greater in animals
that are maintained chronically hyponatremic than in nor-
monatremic animals undergoing similar increases in
plasma osmolality [70–72]; by analogy, the brains of
human patients adapted to hyponatremia are likely to be
particularly susceptible to dehydration following sub-
sequent increases in osmolality, which in turn can lead to
pathological demyelination in some patients. MRI studies
have shown that chronic hypo-osmolality predisposes rats
to opening of the blood–brain barrier following rapid cor-
rection of hyponatremia [73], and that the disruption of
the blood–brain barrier is highly correlated with sub-
sequent demyelination [74]; a potential mechanism by
which blood–brain barrier disruption might lead to sub-
sequent myelinolysis via an influx of complement, which
is toxic to the oligodendrocytes that manufacture and
maintain the myelin sheaths of neurons into the brain
[75]. Of the factors that clearly influence the susceptibility
to demyelination following correction of hyponatremia,
perhaps most important are the severity and duration of
the pre-existing hyponatremia. Both of these risk factors
likely relate to the degree of brain volume regulation that
has occurred prior to the correction: the more severe the
hyponatremia and the longer it has been maintained, the
greater the degree of solute loss that will have occurred
during the process of brain volume regulation. As larger
amounts of solute are lost, the ability of the brain to buffer
subsequent increases in plasma osmolality is impaired, re-
sulting in greater degrees of brain dehydration as serum
[Na+] is later raised, which in turn can lead to brain de-
myelination. Clinical implications of this pathophysiologi-
cal mechanism are that ODS should not occur in cases of
either mild or very acute hyponatremia. Both of these
findings have been found to be true. ODS has only rarely
been reported in patients with a starting serum [Na+]
>120 mmol/L [32, 76, 77], and also does not appear to
occur in most patients with psychogenic polydipsia who
are well known to develop hyponatremia acutely from epi-
sodes of massive water ingestion followed by rapid correc-
tion as they diurese the excess fluid [78]. In cases in which
an overcorrection has already occurred, consideration
should be given to lowering serum [Na+] back to the maxi-
mally desired correction in that patient, again using water
administration and/or desmopressin. Animal models have
suggested that lowering serum [Na+] after overcorrection
can prevent subsequent brain damage from occurring [79,
80], and this would be consistent with the occurrence of a
delayed immunological demyelination as a result of
complement influx into the brain following a sustained
blood–brain barrier disruption [75]. A case report in which
delayed lowering of serum [Na+] was associated with a re-
versal of symptoms suggestive of early myelinolysis also
supports this as a potential therapy in similar cases [81].
However, there is no clinical evidence to support the rec-
ommendation of this for cases of acute hyponatremia, as
in this case. Typical scenarios in which hyponatremia de-
velops acutely are water intoxication from severe polydip-
sia in psychiatric patients, hyponatremia that occurs 24–48
h postoperatively, especially in neurosurgical patients, and
exercise-associated hyponatremia following marathon and
ultramarathon endurance events.
Case 3 is similar to case 1 in that it illustrates a case of
pneumonia-associated SIADH. However, it occurred in a
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patient who represents the patient population at greatest
risk of hyponatremia, namely the elderly. When hypona-
tremia is defined as a serum [Na+] <135 mmol/L, inci-
dences as high as 15–30% have been observed in studies
of both acutely and chronically hospitalized patients [1,
82]. However, incidences decrease to the range of 1–4%
when only patients with serum [Na+] <130–131 mmol/L
are included [13, 83, 84], which may represent a more ap-
propriate level to define the occurrence of clinically signifi-
cant cases of this disorder. Even when one uses these
more stringent criteria to define hypo-osmolality, inci-
dences from 7 to ∼53% have been reported in institutio-
nalized geriatric patients [85, 86]. Many different factors
are responsible for the high prevalence of hyponatremia in
the elderly, including drugs, particularly thiazide diuretics
and selective serotonin reuptake inhibitors antidepress-
ants, low solute diets, underlying co-morbidities such as
heart failure and lung disease, and SIADH of multiple
etiologies. Unexplained or idiopathic causes of SIADH
account for a relatively small proportion of all cases of
SIADH, and the numbers of patients in whom an apparent
cause cannot be established after consistent follow-up
over time are relatively few. However, an exception to this
appears to be elderly patients who sometimes develop
SIADH without any apparent underlying etiology [87–89].
Coupled with the significantly increased incidence of hy-
ponatremia in geriatric patients [1, 85, 86, 90–92], this
suggests that the normal ageing process may be
accompanied by abnormalities of regulation of vasopres-
sin secretion that predispose to SIADH. Such an effect
could potentially account for the fact that virtually all
causes of drug-induced hyponatremia occur much more
frequently in elderly patients [93–95]. In several series of
elderly patients meeting criteria for SIADH, 40–60% re-
mained idiopathic despite rigorous evaluation [96–98].
Also, similar to case 1, this case illustrates initial use of
an ineffective therapy for SIADH, namely isotonic NaCl in-
fusion. Infusion of isotonic saline was shown to be ineffec-
tive in the first patients described to have SIADH by
Schwartz et al. [25]. These seminal studies documented
that in response to saline infusion, the patient increased
urine sodium excretion since there is no stimulus to retain
sodium in a euvolemic patient; the net result was no
change in serum [Na+], though in patients with low or
negative electrolyte-free water excretion, serum [Na+]
may actually decrease [99]. Given what has long been
known about the futility of using isotonic saline in patients
with SIADH, it remains surprising how often this therapy is
employed as the initial therapy of such patients. Luckily, in
this case, the patient was treated more efficaciously fol-
lowing an appropriate evaluation that documented a di-
agnosis of SIADH. In contrast to case 1, utilization of the
urine to plasma electrolyte ratio (Table 5) prevented sub-
sequent employment of fluid restriction as a second inef-
fective treatment, and therapy with tolvaptan allowed the
patient to be discharged sooner than undoubtedly would
have been the case had a fluid restriction been employed.
Case 4 illustrates a case of SIADH produced by small-
cell carcinoma of the lung, the disease of the index cases
of SIADH and still the most common tumor associated
with inappropriately elevated vasopressin levels and hypo-
natremia. It is of interest that this patient was admitted
with a normal sodium level and only became hyponatre-
mic following admission to the hospital. Prof. Peri hypoth-
esizes that this may have been due to the production of
more severe SIADH with the institution of opiate therapy.
This is certainly possible, and would fit the time course of
the hyponatremia. However, it is not uncommon for
patients with SIADH to present with a normal serum [Na+]
as a result of limited fluid intake. This is especially true of
the elderly, who are known to have a decreased thirst
response [100]; in effect, they have a self-imposed fluid re-
striction, but when subjected to intravenous fluids as well
as medications that further reduce free water excretion,
they manifest the hyponatremia characteristic of SIADH.
Evidence in support of a disordered thirst mechanism in
this patient is the development of hypernatremia with tol-
vaptan therapy. Most patients would maintain a normal
serum [Na+] even in the face of vaptan-induced aquaresis
because they increase fluid intake commensurate with in-
creased thirst as they become hyperosmolar.
This case, therefore, emphasizes the need to continue
to follow serum [Na+] after instituting aquaretic therapies,
regardless of the type, especially in elderly patients. It
also illustrates the advisability of not using a fluid restric-
tion in patients started on vaptan therapy because of the
increased risk of increasing the serum [Na+] too rapidly
and/or causing hyperosmolality, both of which are risk
factors for the development of ODS. Finally, the case again
illustrates the inability of therapies such as fluid restriction
to normalize the serum [Na+] when renal electrolyte-free
water excretion is low. Maintaining a serum [Na+] ∼130
mmol/L would be acceptable for most patients, but in this
case, intervening therapy with chemotherapeutic agents
accompanied by the increased fluids that are typically
infused in conjunction with potentially nephrotoxic che-
motherapeutic agents required a larger safety margin,
which was far more effectively accomplished with tolvap-
tan therapy than continued fluid restriction.
Case 5 illustrates a case of hyponatremia accompanying
SAH, one of the most common causes of hyponatremia
with acute neurological injury. Although in some ways
similar to case 2, this case highlights why CSW cannot
account for the development of hyponatremia in most
cases with neurological injury. Typical of many such cases,
the patient was initially assumed to have CSWas a result of
hyponatremia with an elevated urine sodium excretion, but
never actually met criteria for a diagnosis of CSW since
volume depletion resulting from natriuresis was never
documented [101]. Aggressive volume expansion as part of
the triple-H therapy employed in patients with SAH usually
fails to prevent or improve the hyponatremia [64], and
often is accompanied by decreases in serum [Na+] as a
result of the large volumes of fluid infused as a component
of triple-H therapy. When this occurs, therapy with vaptans
is an appropriate consideration to correct the hyponatre-
mia and prevent potentially detrimental increases in intra-
cranial pressure. Concerns about vasospasm must also be
considered, but this can be addressed by preventing
volume depletion by infusing isotonic saline during the
induced aquaresis while carefully monitoring the patient’s
volume status, either by hemodynamic parameters such as
central venous pressure measurements, and/or by routine
intake and output measurements. However, caution must
always be exercised when combining therapies for hypona-
tremia, such as the combined use of tolvaptan and 3% NaCl
in this case, to prevent overly rapid correction of hyponatre-
mia with increased risk of ODS.
Although not specifically illustrated via a case study in
this supplement, a careful drug history is essential in
patients with SIADH as hundreds of different medications
can potentially cause hyponatremia (Table 8) [35].
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Discontinuation of treatment with these agents and
avoidance of readministration is an effective manage-
ment strategy in such cases (Figure 3). Despite the hetero-
geneous nature of these five cases, including age, disease
process, acuity of hyponatremia and symptomatology,
there are significant commonalities across all of the pre-
sented cases that deserve emphasis:
(i) In all cases, the necessary clinical and laboratory
evaluations were eventually, though not always
initially, obtained to make a definitive diagnosis of
SIADH (Table 1). Too often, treatment for hyponatre-
mia is started without performing the analyses
needed to confirm the correct diagnosis (Figure 3).
(ii) In most of the cases, initial therapies were chosen
that were ineffective, or actually worsened the hypo-
natremia, including isotonic saline administration,
NaCl tablets and fluid restriction. These errors could
have been avoided, for the most part, by the evalu-
ation of the patient’s initial presentation.
(iii) More careful initial analysis of the clinical scenario,
importantly including consideration of the urine and
plasma laboratory values, could have led to employ-
ment of more effective therapies sooner, as was de-
monstrated in case 4.
(iv) Severe symptomatic hyponatremia was treated ap-
propriately with 3% NaCl infusion, but this therapy
always entails an increased risk of overly rapid correc-
tion of the hyponatremia. To guard against ODS, the
serum [Na+] must be monitored at frequent intervals
while the active correction is ongoing.
(v) Treatment with vaptan therapy was successful in
cases that were refractory to other therapies, usually
leading to quicker hospital and ICU discharge.
(vi) Attention to the underlying etiology of the SIADH
allowed cessation of vaptan therapy once the patho-
logical process causing the SIADH had resolved
(Figure 12).
Obviously, the above characteristics will not be applicable
to all cases, nor will the treatment decisions made be the
same. However, the cases in aggregate emphasize that
paying attention to known principles of diagnosis and
treatment can result in better outcomes for patients with
hyponatremia from SIADH by choosing initial therapies ac-
cording to a careful analysis of the patient’s presenting
clinical characteristics, rather than indiscriminate employ-
ment of typical therapies that are too often ineffective or
deleterious.
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